DENVER, Jan. 05, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced that President and CEO Patrick Blair will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 3:45 p.m. (PT) / 6:45 p.m. (ET). The presentation will be webcast live, and the webcast link and related presentation materials for the event will be available online on the investor relations section of the Company’s website.
About InnovAge
InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers, and government payors — “win.” As of September 30, 2022, InnovAge served approximately 6,540 participants across 18 centers in five states. https://www.innovage.com/.
Investor Contact:
Ryan Kubota
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Sarah Rasmussen, APR
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.17 |
Daily Change: | -0.29 -6.50 |
Daily Volume: | 48,351 |
Market Cap: | US$564.870M |
February 04, 2025 November 05, 2024 November 04, 2024 October 11, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load